Skip to main content
SpringerLink
Log in

Treatment of Tourette Syndrome

  • Review
  • Published:
Neurotherapeutics

Abstract

Tourette’s syndrome (TS) consists of chronic motor and phonic tics and characteristically begins in childhood. The tics can be disabling and commonly associated behavioral comorbities such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), can also cause problems in daily functioning. The underlying etiology and neurobiology of TS remain unknown although genetic factors appear to be important, cortical control of basal ganglia motor function appears to be disturbed and neurochemical abnormalities, particularly involving dopamine neurotransmission, are likely present. The treatment of TS involves appropriate education and support. Tics can be treated with habit reversal cognitive behavioral therapy, medications (most commonly alpha agonists and antipsychotics), local intramuscular injections of botulinum toxin and some severe, refractory cases have responded to deep brain stimulation surgery (DBS). It is important to appropriately diagnose and treat comorbid behavioral disorders that are disrupting function. OCD can be treated with cognitive behavioral therapy, selective serotonin reuptake inhibitors, and atypical antipsychotics. DBS has become a treatment option for patients with disabling OCD despite other therapies. ADHD is treated with appropriate classroom accommodations, behavioral therapy, alpha agonists, atomoxetine or methylphenidate-containing stimulant drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cheung M-YC, Shahed J, Jankovic J. Malignant Tourette syndrome. Movement Disord. 2007; 22(12):1743–50.

    Article  PubMed  Google Scholar 

  2. Jankovic J, Kurlan R. Tourette syndrome: Evolving concepts. Movement Disord. 2011; 26(6):1149–56.

    Article  PubMed  Google Scholar 

  3. Bronfeld M, Bar-Gad I. Tic Disorders: What Happens in the Basal Ganglia? Neuroscientist. 2013; 19(1):101–8.

    Article  PubMed  Google Scholar 

  4. Orth M, Münchau A, Rothwell JC. Corticospinal system excitability at rest is associated with tic severity in Tourette syndrome. Biol Psychiat. 2008; 64(3):248–51.

    Article  PubMed  Google Scholar 

  5. Rajagopal S, Seri and S, Cavanna AE. Premonitory urges and sensorimotor processing in Tourette syndrome. Behav Neurol. 2013; 27(1):65–73

    Google Scholar 

  6. Kataoka Y, Kalanithi PSA, Grantz H, Schwartz ML, Saper C, Leckman JF, et al. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. The J Compar Neurol. 2010; 518(3):277–91.

    Article  Google Scholar 

  7. Kalanithi PSA, Zheng W, Kataoka Y, DiFiglia M, Grantz H, Saper CB, et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(37):13307–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Lerner A, Bagic A, Simmons JM, Mari Z, Bonne O, Xu B, et al. Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain. 2012; 135(6):1926–36.

    Article  PubMed  Google Scholar 

  9. Piacentini J, Woods DW, Scahill L, Wilhelm S, Peterson AL, Chang S, et al. Behavior therapy for children with Tourette disorder. JAMA. 2010; 303(19):1929–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Roessner V, Plessen K, Rothenberger A, Ludolph A, Rizzo R, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiat. 2011; 20(4):173–96.

    Article  Google Scholar 

  11. Scahill L, Erenberg G, Berlin Jr CM, Budman C, Coffey BJ, Jankovic J, et al. Contemporary Assessment and Pharmacotherapy of Tourette Syndrome. NeuroRX. 2006; 3(2):192–206.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Tourette's Syndrome Study Group. Short-term versus longer term pimozide therapy in Tourette's syndrome. Neurology. 1999; 52:874–7.

    Article  Google Scholar 

  13. Müller-Vahl KR, Krueger D. Does Tourette syndrome prevent tardive dyskinesia? Movement Disord. 2011; 26(13):2442–3.

    Article  PubMed  Google Scholar 

  14. Dion Y, Annabele L, Sandor P, Chouinard G. Risperidone in the treatment of Tourette syndrome: A double-blind, placebo-controlled trial. J Clin Psychopharm. 2002; 22:31–9.

    Article  CAS  Google Scholar 

  15. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003; 69:1130–5.

    Article  Google Scholar 

  16. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Movement Disord. 2011; 26(1):147–52.

    Article  PubMed  Google Scholar 

  17. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and ADHD. Am J Psychiatry. 2001; 158:1067–74.

    Article  CAS  PubMed  Google Scholar 

  18. Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ. Clonidine treatment of Gilles de la Tourette syndrome. Arch Gen Psychiatry. 1991; 48:324–8.

    Article  CAS  PubMed  Google Scholar 

  19. Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D. Tourettes Syndrome and Role of Tetrabenazine: Review and Personal Experience. Clin Drug Invest. 2008; 28(7):443–59.

    Article  CAS  Google Scholar 

  20. Kenney CJ, Hunter CB, Mejia NI, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J Ped Neurol. 2007; 5(1):9–13.

    CAS  Google Scholar 

  21. Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications. Expert Opinion on Orphan Drugs. 2013; 1(5):423–36.

    Google Scholar 

  22. Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosur Ps. 2010; 81(1):70–3.

    Article  CAS  Google Scholar 

  23. Kurlan R, Crespi G, Coffey B, Muller-Vahl K, Koval S, Wunderlich G, Pramipexole for TS Trial Investigators. A multi-center randomized placebo-controlled trial of pramipexole in Tourette's syndrome. Movement Disord. 2012; 27:775–8.

    Google Scholar 

  24. Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol. 2000; 57(8):1190–3.

    Article  CAS  PubMed  Google Scholar 

  25. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Neurology. 2008; 70(19):1699–706.

    Article  CAS  PubMed  Google Scholar 

  26. Maciunas RJ, Maddux BN, Riley DE, Whitney CM, Schoenberg MR, Ogrocki PJ, et al. Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome. J Neurosurg. 2007; 107(5):1004–14.

    Article  PubMed  Google Scholar 

  27. Servello D, Porta M, Sassi M, Brambilla A, Robertson MM. Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation. J Neurol Neurosur Ps. 2008; 79(2):136–42.

    Article  CAS  Google Scholar 

  28. Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. Stereotactic and Functional Neurosurgery. 2012; 90(4):213–24.

    Article  PubMed  Google Scholar 

  29. Tourette's Syndrome Study Group. Treatment of ADHD in children with Tourette's syndrome (TACT Trial). Ann Neurol. 2000; 48:953

    Google Scholar 

  30. Gadow KD, Sverd J, Nolan EE, Sprafkin J, Schneider J. Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7):840–8.

    Article  PubMed  Google Scholar 

  31. Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005; 65(12):1941–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Author information

Authors and Affiliations

  1. Movement Disorders Program, Atlantic Neuroscience Institute, Overlook Medical Center, 99 Beauvoir Avenue, Summit, NJ, 07902, USA

    Roger M. Kurlan

Authors
  1. Roger M. Kurlan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger M. Kurlan.

Additional information

Invited Review for Movement Disorders Therapeutics, in NeuroTherapeutics, Jankovic J and Factor S (editors)

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 1224 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurlan, R.M. Treatment of Tourette Syndrome. Neurotherapeutics 11, 161–165 (2014). https://doi.org/10.1007/s13311-013-0215-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13311-013-0215-4

Keywords

Search

Navigation